← 홈

Antibody · 혈액암 (AML/ALL)

286개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 286개
AntibodystaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAbbViePhase 1

Pivekimab Sunirine (Pivekimab Sunirine)

Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Olaparib; Bevacizumab (QLS5132; Olaparib; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Tislelizumab+carboplatin)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Rituximab (Mabthera, Rituximab, Rituximab (Mabthera) , FFP (Fresh Frozen Plasma))

Advanced Refractory Chronic Lymphocytic Leukemia · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Rituximab + zanubrutinib + lenalidomide (Rituximab + zanubrutinib + lenalidomide)

Overall Survival · Overall Survival

#OverallSurvival#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Rituximab+mVPDL (Rituximab+mVPDL)

Precursor Cell Lymphoblastic Leukemia-Lymphoma · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C (Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C)

B-cell Non Hodgkin Lymphoma; Mature B-cell Leukemia Burkitt-type · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Rucaparib and Nivolumab)

Small Cell Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 4%임상시험 1상태 ACTIVE
AntibodystaleSanofiPhase 2

Tusamitamab ravtansine (SAR408701, SAR408701 (Tusamitamab ravtansine))

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · Non-squamous Non-small-cell Lung Cancer

#Non-squamousNon-small-cellLungCa#Antibody#Phase2#항체#면역항체+2
효능 ORR 66.7%임상시험 1상태 DISCONTINUED
AntibodyBiologicstaleSeagen Inc.Phase 2

anti-huCD40 mAb (SGN-40, SGN-40 (anti-huCD40 mAb))

Leukemia, Lymphocytic, Chronic · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleNational Cancer Centre, Singapo…Phase 2

atezolizumab (Tecentriq, SIRT-Y90 with Atezolizumab + Bevacizumab)

Locally Advanced Hepatocellular Carcinoma · Locally Advanced Hepatocellular Carcinom

#LocallyAdvancedHepatocellularCar#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleShanghai Henlius BiotechPhase 3

carboplatin-etoposide (Serplulimab + chemotherapy, Serplulimab + chemotherapy (carboplatin-etoposide))

Extensive Stage Small Cell Lung Cancer · Extensive Stage Small Cell Lung Cancer

#ExtensiveStageSmallCellLungCance#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Serplulimab combined with bevacizumab and first-line chemotherapy (Serplulimab combined with bevacizumab and first-line chemotherapy)

Non-small Cell Lung Cancer Stage II; Bevacizumab · Non-small Cell Lung Cancer Stage II

#Non-smallCellLungCancerStageII#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleFirst Affiliated Hospital of We…Phase 2

Serplulimab immunotherapy (Serplulimab immunotherapy)

Locally Advanced Rectal Cancer (LARC) · Locally Advanced Rectal Cancer (LARC)

#LocallyAdvancedRectalCancerLARC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleXin-Hua XuPhase 2

Sindillimab (Sindillimab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleInnoventPhase 2

Sintilimab with Interleukin-2+CAPOX (Sintilimab with Interleukin-2+CAPOX)

Locally Advanced Rectal Adenocarcinoma · Locally Advanced Rectal Adenocarcinoma

#LocallyAdvancedRectalAdenocarcin#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleBeijing Chest HospitalPhase 2

Surufatinib Durvalizumab EP/EC (Surufatinib Durvalizumab EP/EC)

Extensive-stage Small-cell Lung Cancer · Extensive-stage Small-cell Lung Cancer

#Extensive-stageSmall-cellLungCan#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE

12 / 15 페이지

← 이전다음 →